JENA / LONDON (IT BOLTWISE) – The Carl Zeiss Meditec share is currently showing a downward trend, which concerns investors and analysts alike. Despite a recent 52-week low, the company remains optimistic about future earnings and dividends. Experts forecast a profit of EUR 1.72 per share for 2025, which indicates a positive development.
Today’s daily deals at Amazon! ˗ˋˏ$ˎˊ˗
The Carl Zeiss Meditec share fell 0.9 percent in XETRA trading on Tuesday afternoon and was quoted at EUR 41.02. The price temporarily fell to a 52-week low of EUR 40.30, which increased uncertainty among investors. The trading day started at EUR 40.84 and a total of 53,145 shares were traded.
On March 20, 2025, the stock reached a 52-week high of EUR 71.65, representing a decline of 42.75 percent compared to the current price. This volatility reflects the challenges the Company faces while navigating a dynamic market environment.
In 2024, shareholders received a dividend of EUR 0.600 per share. A distribution of EUR 0.693 is expected for the current year, which represents a slight increase. This dividend policy shows the company’s commitment to providing its shareholders with stable income despite the current market fluctuations.
Analysts forecast earnings of EUR 1.72 per share for 2025, which indicates a positive development. This assessment is based on the expectation that Carl Zeiss Meditec will further strengthen its market position through innovations and strategic investments.
The share is part of the TecDAX, which makes it particularly interesting for investors who want to invest in German technology companies. Experts consider the company’s long-term prospects to be promising, especially given the growing demand for medical technologies.
Order an Amazon credit card without an annual fee with a credit limit of 2,000 euros!
Bestseller No. 1 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 2 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 3 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 4 ᵃ⤻ᶻ “KI Gadgets”
Bestseller No. 5 ᵃ⤻ᶻ “KI Gadgets”
Please send any additions and information to the editorial team by email to de-info[at]it-boltwise.de. Since we cannot rule out AI hallucinations, which rarely occur with AI-generated news and content, we ask you to contact us via email and inform us in the event of false statements or misinformation. Please don’t forget to include the article headline in the email: “Carl Zeiss Meditec: Current developments and market assessments”.